Idioma:

Targeting phosphodiesterase 4 as a potential therapy for Parkinson’s disease: a review

Nongthombam, Pooja Devi ; Haobam, Reena

Molecular biology reports, 2024-12, Vol.51 (1), p.510-510, Article 510 [Periódico revisado por pares]

Dordrecht: Springer Netherlands

Texto completo disponível

Citações Citado por

Enviar para

Título:
Targeting phosphodiesterase 4 as a potential therapy for Parkinson’s disease: a review
Autor: Nongthombam, Pooja Devi ; Haobam, Reena
Assuntos: Adenosine ; Animal Anatomy ; Animal Biochemistry ; Animals ; Apoptosis ; Biomedical and Life Sciences ; Cell death ; Central nervous system ; Chronic obstructive pulmonary disease ; Cyclic AMP ; Cyclic AMP - metabolism ; Cyclic GMP ; Cyclic GMP - metabolism ; Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism ; Diethylstilbestrol - analogs & derivatives ; Dopamine ; Dopamine receptors ; Drug development ; Drugs ; Enzymes ; FDA approval ; Histology ; Humans ; Kinases ; Life Sciences ; Mammals - metabolism ; Molecular biology ; Morphology ; Movement disorders ; Nervous system ; Neurodegeneration ; Neurodegenerative diseases ; Neurodegenerative Diseases - metabolism ; Neurological diseases ; Neurons ; Oxidative stress ; Parkinson Disease - drug therapy ; Parkinson's disease ; Phosphodiesterase ; Phosphodiesterase 4 Inhibitors - pharmacology ; Phosphodiesterase 4 Inhibitors - therapeutic use ; Phosphodiesterase IV ; Phosphorylation ; Proteins ; Review ; Signal transduction ; Therapeutic targets
É parte de: Molecular biology reports, 2024-12, Vol.51 (1), p.510-510, Article 510
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Phosphodiesterases (PDEs) have become a promising therapeutic target for various disorders. PDEs are a vast and diversified family of enzymes that degrade cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which have several biochemical and physiological functions. Phosphodiesterase 4 (PDE4) is the most abundant PDE in the central nervous system (CNS) and is extensively expressed in the mammalian brain, where it catalyzes the hydrolysis of intracellular cAMP. An alteration in the balance of PDE4 and cAMP results in the dysregulation of different biological mechanisms involved in neurodegenerative diseases. By inhibiting PDE4 with drugs, the levels of cAMP inside the cells could be stabilized, which may improve the symptoms of mental and neurological disorders such as memory loss, depression, and Parkinson’s disease (PD). Though numerous studies have shown that phosphodiesterase 4 inhibitors (PDE4Is) are beneficial in PD, there are presently no approved PDE4I drugs for PD. This review presents an overview of PDE4Is and their effects on PD, their possible underlying mechanism in the restoration/protection of dopaminergic cell death, which holds promise for developing PDE4Is as a treatment strategy for PD. Methods on how these drugs could be effectively delivered to develop as a promising treatment for PD have been suggested.
Editor: Dordrecht: Springer Netherlands
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 2 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Targeting phosphodiesterase 4 as a potential therapy for Parkinson’s disease: a review

Nongthombam, Pooja Devi ; Haobam, Reena

Dordrecht: Springer Netherlands

Buscando em bases de dados remotas. Favor aguardar.